Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :851
Small font sizeDefault font sizeIncrease font size
Resource Links
     Search Pubmed for
 
    -  Thakur S
    -  Lahiry S
 

 Article Access Statistics
    Viewed643    
    PDF Downloaded15    

Recommend this journal

 

 VIEWPOINT

Accelerated drug approvals in oncology: Pros and cons


1 Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
2 Independent Scholar, Kolkata, West Bengal, India

Correspondence Address:
Sayanta Thakur,
Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_793_19

PMID: 33402558

The inevitable surge of the accelerated approval process, especially for oncology drugs, has been a success story. However, the use of surrogate end-points and its validation has been debatable over the years. Over the years, US Food and Drug Administration has been rigorously working for the validation of these end-points to capture the real clinical benefit and appropriateness of clinical study designs. However, the high cost imposed by the manufacturer attributed to the faster drug access can be prohibitive and well undermine the whole process. We discuss issues that must be addressed and solved accordingly for managed care in oncology.




  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow